Entities / Company
OPKO Health (Ireland).
company in Waterford, Ireland
- Reports this week
- 0
- Active events
- 0
- Connections
- 28
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
OPKO Health is scheduled to present its treatment in Prague on August 1st, while Trump-era tariffs continue to benefit certain AI stocks.Some support1 report
-
OPKO Health announced a partnership and new data presentation for its investigational drug OPK-88006 at the ENDO 2025 conference, drawing attention from financial firms like Goldman Sachs and David Tepper.Speculative2 reports
-
OPKO Health (Ireland) and Entera Bio Ltd. collaborated on the development of an oral GLP-2 analog therapy.Some support2 reports
-
OPKO Health (Ireland) stock performance was compared to the broader market on August 1, 2025.Some support1 report
-
OPKO Health reported that a Barda contract increased IP transfer revenue, while lower gross profit share payments reduced revenue.Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 3 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
LabCorp Transactional
OPKO sold and planned to sell oncology and diagnostics assets to LabCorp.
-
Phillip Frost Structural
Phillip Frost serves as the Chairman, CEO, and largest shareholder of OPKO Health.
-
Merck Operational
OPKO Health and Merck are actively collaborating on the development and advancement of an Epstein-Barr virus vaccine candidate.
History
Events by the month they beganJune 2026
7 events- Phillip Frost was appointed Chairman and CEO of OPKO Health.
- OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.
- OPKO Health is scheduled to present its treatment in Prague on August 1st, while Trump-era tariffs continue to benefit certain AI stocks.
- OPKO Health announced a partnership and new data presentation for its investigational drug OPK-88006 at the ENDO 2025 conference, drawing attention from financial firms like Goldman Sachs and David Tepper.
- OPKO Health (Ireland) and Entera Bio Ltd. collaborated on the development of an oral GLP-2 analog therapy.
- OPKO Health (Ireland) stock performance was compared to the broader market on August 1, 2025.
- OPKO Health reported that a Barda contract increased IP transfer revenue, while lower gross profit share payments reduced revenue.